JP2020523038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523038A5 JP2020523038A5 JP2020518571A JP2020518571A JP2020523038A5 JP 2020523038 A5 JP2020523038 A5 JP 2020523038A5 JP 2020518571 A JP2020518571 A JP 2020518571A JP 2020518571 A JP2020518571 A JP 2020518571A JP 2020523038 A5 JP2020523038 A5 JP 2020523038A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- cells
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023097445A JP7596447B2 (ja) | 2017-06-08 | 2023-06-14 | Ｃｄ３８調節抗体 |
| JP2024205869A JP7860205B2 (ja) | 2017-06-08 | 2024-11-27 | Ｃｄ３８調節抗体 |
Applications Claiming Priority (33)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517150P | 2017-06-08 | 2017-06-08 | |
| US201762517149P | 2017-06-08 | 2017-06-08 | |
| US62/517,150 | 2017-06-08 | ||
| US62/517,149 | 2017-06-08 | ||
| US201762517753P | 2017-06-09 | 2017-06-09 | |
| US201762517165P | 2017-06-09 | 2017-06-09 | |
| US201762517740P | 2017-06-09 | 2017-06-09 | |
| US201762517164P | 2017-06-09 | 2017-06-09 | |
| US201762517745P | 2017-06-09 | 2017-06-09 | |
| US201762517734P | 2017-06-09 | 2017-06-09 | |
| US62/517,164 | 2017-06-09 | ||
| US62/517,734 | 2017-06-09 | ||
| US62/517,745 | 2017-06-09 | ||
| US62/517,165 | 2017-06-09 | ||
| US62/517,753 | 2017-06-09 | ||
| US62/517,740 | 2017-06-09 | ||
| US201762546322P | 2017-08-16 | 2017-08-16 | |
| US201762546330P | 2017-08-16 | 2017-08-16 | |
| US62/546,322 | 2017-08-16 | ||
| US62/546,330 | 2017-08-16 | ||
| US201762582628P | 2017-11-07 | 2017-11-07 | |
| US201762582666P | 2017-11-07 | 2017-11-07 | |
| US201762582676P | 2017-11-07 | 2017-11-07 | |
| US201762582681P | 2017-11-07 | 2017-11-07 | |
| US201762582653P | 2017-11-07 | 2017-11-07 | |
| US201762582616P | 2017-11-07 | 2017-11-07 | |
| US62/582,666 | 2017-11-07 | ||
| US62/582,653 | 2017-11-07 | ||
| US62/582,616 | 2017-11-07 | ||
| US62/582,628 | 2017-11-07 | ||
| US62/582,676 | 2017-11-07 | ||
| US62/582,681 | 2017-11-07 | ||
| PCT/EP2018/065237 WO2018224682A1 (en) | 2017-06-08 | 2018-06-08 | Cd38 modulating antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097445A Division JP7596447B2 (ja) | 2017-06-08 | 2023-06-14 | Ｃｄ３８調節抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523038A JP2020523038A (ja) | 2020-08-06 |
| JP2020523038A5 true JP2020523038A5 (enExample) | 2021-07-26 |
| JP7679196B2 JP7679196B2 (ja) | 2025-05-19 |
Family
ID=62620845
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518571A Active JP7679196B2 (ja) | 2017-06-08 | 2018-06-08 | Ｃｄ３８調節抗体 |
| JP2023097445A Active JP7596447B2 (ja) | 2017-06-08 | 2023-06-14 | Ｃｄ３８調節抗体 |
| JP2024205869A Active JP7860205B2 (ja) | 2017-06-08 | 2024-11-27 | Ｃｄ３８調節抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097445A Active JP7596447B2 (ja) | 2017-06-08 | 2023-06-14 | Ｃｄ３８調節抗体 |
| JP2024205869A Active JP7860205B2 (ja) | 2017-06-08 | 2024-11-27 | Ｃｄ３８調節抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11780930B2 (enExample) |
| EP (1) | EP3635001A1 (enExample) |
| JP (3) | JP7679196B2 (enExample) |
| CN (2) | CN111051344B (enExample) |
| AU (2) | AU2018280868B2 (enExample) |
| CA (1) | CA3066547A1 (enExample) |
| WO (1) | WO2018224682A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110144008B (zh) | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| CN114761430A (zh) * | 2019-09-26 | 2022-07-15 | 奥里尼斯生物科学股份有限公司 | 靶向pd-l1的嵌合蛋白及其用途 |
| CN114616245B (zh) * | 2019-12-13 | 2024-02-23 | 山东先声生物制药有限公司 | 一种抗cd38的抗体及其用途 |
| WO2021259227A1 (zh) * | 2020-06-23 | 2021-12-30 | 江苏康缘药业股份有限公司 | 抗cd38抗体及其用途 |
| CN114075283A (zh) | 2020-08-12 | 2022-02-22 | 三生国健药业（上海）股份有限公司 | 结合人cd38的抗体、其制备方法和用途 |
| CN116635420A (zh) * | 2020-09-10 | 2023-08-22 | 英创远达制药公司 | 血液筛查方法 |
| US12181485B2 (en) | 2020-09-10 | 2024-12-31 | CASI Pharmaceuticals, Inc | Methods of blood screening |
| CN114437215B (zh) * | 2020-11-05 | 2023-02-07 | 上海麦济生物技术有限公司 | 抗人cd38抗体及其制备方法和用途 |
| KR20250131813A (ko) * | 2023-01-05 | 2025-09-03 | 다나-파버 캔서 인스티튜트 인크. | Kit 세포-표면 수용체의 에피토프 조작 |
| WO2025166138A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + tslp targeting antibodies and uses thereof |
| WO2025166146A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + ox40 targeting antibodies and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| AU2011202520C1 (en) | 2002-10-17 | 2016-02-18 | Genmab A/S | Human monoclonal antibodies against CD20 |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| EP2915820A1 (en) * | 2004-02-06 | 2015-09-09 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) * | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CN101287764B (zh) | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| AU2016228249A1 (en) | 2006-09-26 | 2016-10-06 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| AU2013209322A1 (en) * | 2006-10-19 | 2013-08-15 | Sanofi-Aventis | Novel anti-cd38 antibodies for the treatment of cancer |
| SG177168A1 (en) | 2006-12-01 | 2012-01-30 | Medarex Inc | Human antibodies that bind cd22 and uses thereof |
| CN101605906A (zh) * | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
| US20100150950A1 (en) | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2342220B1 (en) * | 2008-10-06 | 2021-05-12 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
| KR101545914B1 (ko) | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
| MX381912B (es) | 2010-07-16 | 2025-03-13 | Adimab Llc | Colecciones de anticuerpos. |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| BR112015021521A2 (pt) | 2013-03-15 | 2017-10-10 | Genentech Inc | anticorpos anti-crth2 e métodos para seu uso |
| JP2017506640A (ja) | 2014-02-14 | 2017-03-09 | セントローズ， エルエルシー | 細胞外標的化薬物共役体 |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| PL3122781T3 (pl) | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| WO2016089862A1 (en) | 2014-12-01 | 2016-06-09 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| CN113527495A (zh) | 2015-04-08 | 2021-10-22 | 索伦托药业有限公司 | 与cd38结合的抗体治疗剂 |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| EP3313441B1 (en) | 2015-06-24 | 2024-02-21 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| MY206406A (en) | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| US12590171B2 (en) | 2019-09-27 | 2026-03-31 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH domain antibodies and use thereof |
-
2018
- 2018-06-08 US US16/620,584 patent/US11780930B2/en active Active
- 2018-06-08 JP JP2020518571A patent/JP7679196B2/ja active Active
- 2018-06-08 CA CA3066547A patent/CA3066547A1/en active Pending
- 2018-06-08 CN CN201880049280.1A patent/CN111051344B/zh active Active
- 2018-06-08 EP EP18731392.9A patent/EP3635001A1/en active Pending
- 2018-06-08 CN CN202311290186.4A patent/CN117534754A/zh active Pending
- 2018-06-08 AU AU2018280868A patent/AU2018280868B2/en active Active
- 2018-06-08 WO PCT/EP2018/065237 patent/WO2018224682A1/en not_active Ceased
-
2023
- 2023-06-14 JP JP2023097445A patent/JP7596447B2/ja active Active
- 2023-09-01 US US18/460,069 patent/US12698338B2/en active Active
-
2024
- 2024-11-11 AU AU2024259884A patent/AU2024259884A1/en active Pending
- 2024-11-27 JP JP2024205869A patent/JP7860205B2/ja active Active